Outcome of the Respiratory Syncytial Virus related acute lower respiratory tract infection among hospitalized newborns: A prospective multicenter study
No Thumbnail Available
Date
2016
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Aim: To determine the incidence and outcomes of respiratory syncytial virus (RSV)-related acute lower respiratory tract infection (ALRI) including morbidity, nosocomial infection and mortality among newborn infants who were admitted to the neonatal intensive care units (NICUs).Methods: A multicenter, prospective study was conducted in newborns who were hospitalized with community acquired or nosocomial RSV infection in 44 NICUs throughout Turkey. Newborns with ALRI were screened for RSV infection by Respi-Strip®-test. Main outcome measures were the incidence of RSV-associated admissions in the NICUs and morbidity, mortality and epidemics results related to these admissions.Findings: The incidence of RSV infection was 1.24% (n: 250) and RSV infection constituted 19.6% of all ALRI hospitalizations, 226 newborns (90.4%) had community-acquired whereas 24 (9.6%) patients had nosocomial RSV infection in the NICUs. Of the 250 newborns, 171 (68.4%) were full-term infants, 183 (73.2%) had a BW >2500 g. RSV-related mortality rate was 1.2%. Four NICUs reported seven outbreaks on different months, which could be eliminated by palivizumab prophylaxis in one NICU.Conclusion: RSV-associated ALRI both in preterm and term infants accounts an important percent of hospitalizations in the season, and may threat other high-risk patients in the NICU. © 2015 Taylor & Francis.
Description
Keywords
Antiviral Agents , Cross Infection , Disease Outbreaks , Female , Hospitalization , Humans , Infant , Infant, Newborn , Infant, Newborn, Diseases , Intensive Care Units, Neonatal , Male , Palivizumab , Prognosis , Prospective Studies , Respiratory Syncytial Virus Infections , Respiratory Syncytial Viruses , Respiratory Tract Infections , Treatment Outcome , Turkey , acetylcysteine , adrenalin , corticosteroid , dornase alfa , ipratropium bromide , macrolide , monoclonal antibody , oxygen , palivizumab , pyroxylin , salbutamol , sodium chloride , antivirus agent , Article , artificial ventilation , atelectasis , bacterial infection , body weight , community acquired infection , diagnostic kit , diagnostic test accuracy study , female , hospital admission , hospital infection , hospital patient , human , Human respiratory syncytial virus , incidence , lower respiratory tract infection , major clinical study , male , morbidity , multicenter study , newborn , newborn intensive care , newborn mortality , noninvasive ventilation , oxygen therapy , predictive value , prematurity , priority journal , prognosis , prophylaxis , prospective study , respiratory syncytial virus infection , screening test , seasonal variation , sensitivity and specificity , Turkey (republic) , clinical trial , cross infection , epidemic , hospitalization , Human respiratory syncytial virus , infant , Infant, Newborn, Diseases , neonatal intensive care unit , prognosis , Respiratory Syncytial Virus Infections , Respiratory Tract Infections , statistics and numerical data , treatment outcome , Turkey